Fesoterodine on Urgency Episodes in Parkinson's Disease Population
Status:
Terminated
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) causes several non-motor autonomic symptoms including lower urinary
tract dysfunction. Their symptoms can be managed with antimuscarinics with variable efficacy.
Fesoterodine offers a new therapeutic molecule to target the symptoms of urinary frequency,
urgency and nocturia in this patient population. The purpose of this protocol is to compare
the impact of fesoterodine to placebo on urinary urgency and nocturnal sleep problems in a
heterogeneous population of PD patients in a cross-over fashion.
A representative number of patients with baseline overactive bladder (OAB) symptoms and
Parkinson's disease will be recruited to receive either the active drug or placebo for the
first phase of eight weeks. The groups will then be crossed-over during the second phase of
eight weeks. The main outcomes assessed will be the urgency episodes on a 3-day voiding
diary, as well as the nocturnal sleep problems will be the Parkinson's Disease Sleep Scale
(PDSS).